The SNP Genotyping and Analysis Market, estimated at USD 30.01 Bn in 2025, is expected to exhibit a CAGR of 21.9% and reach USD 120.03 Bn by 2032.
The market growth is fueled by rising demand for advanced biotechnology solutions that improve healthcare outcomes, along with increasing adoption in areas such as drug development, diagnostics, and personalized medicine. Innovations in genomics, cell and gene therapies, and biomanufacturing, supported by strong R&D investments, are enhancing treatment effectiveness, efficiency, and accessibility. Furthermore, favorable regulatory support, strategic collaborations, and the growing focus on precision medicine are accelerating market expansion and opening new opportunities for industry participants.
New product launches by key market players
The SNP genotyoing and analysis market is anticipated to develop at a significant growth rate during the projected period attributed to the launch of new products by key market players. For instance, in March 2025, Thermo Fisher Scientific, a global leader in science service, has announced the launch of the Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel, a customisable menu of 22 confirmed real-time polymerase chain reaction (PCR) assays for identifying SARS-CoV-2 mutations. These assays allow scientists to choose which mutations to study and enable surveillance of variants causing COVID-19 infections in specific places across the globe.
Global SNP Genotyping and Analysis Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and resulting lockdowns in numerous nations around the world have had an influence on the financial status of companies in all industries, including the SNP genotyping and analysis industry. Many COVID-19 patients experience severe respiratory infections that required hospitalisation and mechanical ventilation. The governments of many nations were focused on steps to combat the COVID-19 pandemic and to halt the spread of coronavirus infection in their individual countries by implementing various measures such as isolation and quarantine facilities, disease surveillance and testing, etc.
The COVID-19 pandemic had a moderate impact on the SNP genotyping and analysis market as these technologies were utilized for detection of the virus strain however, limited availability of skilled technicians hindered large scale usage. Reseaach studies were conducted by several institutes to demonstrate the effectiveness of SNP genotyping for identifying and monitoring circulating SARS-CoV-2 variants. According to a study published on Medrxiv, in January 2025, The Variant Task Force (VTF) of The National Institutes of Health's (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative chose specific SARS-CoV-2 lineages to detect and monitor emerging strains of COVID-19.
Between November and December 2025, 1,128 samples (1,031 SARS-CoV-2 positives and 97 negatives) were collected and analysed retrospectively from two Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories participating in the CDC National SARS-CoV-2 Strain Surveillance (NS3) sequencing program. The study shows that the Omicron variation may be recognised with high accuracy using two to three markers. Combining Omicron-specific markers with those previously used to find variations can give a framework for detecting new variants.
Global SNP Genotyping and Analysis Market: Key Developments
To boost the research studies in genomic medicine market players are coming up with novel sequencing systems thus, strengthening the market development. For instance, in September 2025, Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced the availability of the NovaSeq X Series (NovaSeq X and NovaSeq X Plus), two new production-scale sequencers that will push the boundaries in genomic medicine by enabling faster, more powerful, and more sustainable sequencing. Using state-of-the-art technology, NovaSeq X Plus can generate more than 20,000 whole genomes per year – 2.5 times the throughput of previous sequencers– dramatically increasing genomic discoveries and clinical insights, allowing scientists to better understand disease and, ultimately, improve patient lives.